Monitoring how a colorectal cancer medication works in everyday patient care

This is a monitoring study of Fruzaqla (fruquintinib), a medication approved to treat metastatic colorectal cancer — cancer that has spread beyond the colon. Rather than testing whether the medication works, this study watches how it performs and what side effects patients experience when they take it as part of their regular medical care. The goal is to understand the real-world safety profile of this treatment.

Even after a medication is approved and available to patients, it's important to keep track of how it works in everyday use and what side effects people actually experience. This study will help doctors and the company better understand the safety of this medication when used by a wider range of patients.